首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   204篇
  免费   18篇
  国内免费   2篇
妇产科学   7篇
基础医学   35篇
口腔科学   3篇
临床医学   13篇
内科学   27篇
神经病学   7篇
特种医学   8篇
外国民族医学   1篇
外科学   8篇
综合类   21篇
预防医学   5篇
眼科学   1篇
药学   62篇
中国医学   3篇
肿瘤学   23篇
  2023年   7篇
  2022年   2篇
  2021年   8篇
  2020年   5篇
  2019年   9篇
  2018年   7篇
  2017年   6篇
  2016年   13篇
  2015年   9篇
  2014年   13篇
  2013年   18篇
  2012年   10篇
  2011年   15篇
  2010年   17篇
  2009年   14篇
  2008年   10篇
  2007年   9篇
  2006年   14篇
  2005年   8篇
  2004年   10篇
  2003年   8篇
  2002年   5篇
  2001年   1篇
  1999年   2篇
  1994年   2篇
  1985年   1篇
  1984年   1篇
排序方式: 共有224条查询结果,搜索用时 15 毫秒
1.
目的:研究小剂量阿奇霉素联合噻托溴铵粉吸入剂治疗稳定期 COPD 临床可行性分析及对炎症细胞因子的影响。方法选取2014年3月至2016年3月在我院进行治疗的100例稳定期COPD 患者,根据治疗方案的不同将患者随机分为噻托溴铵单药组(A 组)50例,阿奇霉素联合噻托溴铵组(B 组)50例。另选择同期健康体验者50名为正常对照组(NS 组)提供血液样本。按照2013版 COPD 诊疗指南,在常规治疗的基础上,A 组给予噻托溴铵粉吸入剂吸入治疗,B 组给予阿奇霉素口服联合噻托溴铵粉吸入剂吸入治疗。治疗1年后观察各组急性加重住院次数和治疗前后的肺功能、呼吸困难评分和 C 反应蛋白等指标的变化,并分别于治疗前和治疗后12、24、48 h 取各组患者血清进行酶联免疫吸附测定试验(enzyme linked immunosorbent assay,ELISA)检测患者血液中炎症细胞因子 PTX3、肿瘤坏死因子α(TNF-α)、干扰素-γ(IFN-γ)、IL-2、IL-6的含量并与 NS 组进行对比。结果各组患者的不良反应较轻,差异无统计学意义(P >0.05);与 A 组比较,B 组1年后发作频率、FEV1%、FEV1/FVC 相对较低,差异具有统计学意义(P <0.05);C 反应蛋白和呼吸困难评分 B 组改善高于 A 组,组间比较差异有统计学意义(P <0.05);与 NS 组相比,A、B 组患者 TNF-α、PTX3明显增高,差异有统计学意义(P <0.05);A 组治疗后12、24、48 h 的炎症细胞因子 TNF-α、PTX3与治疗前相比,差异无统计学意义(P >0.05),B 组治疗后 TNF-α和 PTX3逐渐降低并恢复至正常值,差异有统计学意义(P <0.01);其他炎症细胞因子虽有稍微降低,但是差异无统计学意义(P >0.05)。结论服用小剂量阿奇霉素联合噻托溴铵粉吸入剂治疗可以改善稳定期 COPD 患者的肺功能和活动耐力,提高生活质量,减少急性发作频率,其机制可能与其能够降低血液中的 PTX3、TNF-α含量有关。  相似文献   
2.
正五聚蛋白(pentraxin, PTX)3是一类长链 PTX,作为一种炎性标记物,其血浆水平在动脉粥样硬化、心血管疾病、感染、炎症、自身免疫性疾病或组织损伤等情况下升高。最近的研究显示,血浆 PTX3水平在缺血性脑血管病急性期迅速升高。检测血浆 PTX3水平可能有助于急性脑梗死的诊断、治疗和预后判断。  相似文献   
3.
Aim of the workThis work aimed to evaluate serum pentraxin 3 (PTX3) levels in rheumatoid arthritis (RA) patients and to study the association with the disease activity.Patients and methodsSixty RA patients and 26 matched controls were included. In patients, clinical examination was performed and disease activity score (DAS28) assessed. Serum PTX3, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were measured.ResultsThe mean age of the patients was 54.9 ± 11.7 years, and the median (Min–Max) of disease duration was 24 (3.96–60) months and 91.7% were females. The mean DAS28 was 4.16 ± 1.77, the ESR was 38.6 ± 23.03 mm/1st h, CRP was 14.9 ± 8.6 mg/l, RF was 49.6 ± 28.1 IU/ml and the median anti-CCP was 375. Serum PTX3 level was significantly higher in RA patients (2.82 ± 0.48 pg/ml) compared to controls (2.56 ± 0.29 pg/ml) (p = 0.003). There was a significant difference in serum PTX3 level according to the disease activity: remission (2.49 ± 0.16 pg/ml), low (2.61 ± 0.33 pg/ml), moderate (2.90 ± 0.53 pg/ml) and high (3.01 ± 0.51 pg/ml) (p = 0.016). There was a significant correlation between serum PTX3 level with disease activity (r = 0.39, p = 0.002) and CRP (r = 0.49, p < 0.001). There was no significant correlation between serum PTX3 level and the RF (r = 0.25, p = 0.054), anti-CCP (r = 0.18, p = 0.17) and ESR (r = 0.09, p = 0.51). PTX3 and CRP showed a good sensitivity and specificity in predicting RA disease (p = 0.006 and p < 0.001, respectively).ConclusionPTX3 can be considered as a marker of a positive acute phase response and may serve as a potential novel biomarker for detecting RA activity.  相似文献   
4.
5.
Over the recent couple of decades, pharmaceutical field has embarked most phenomenal noteworthy achievements in the field of medications as well as drug delivery. The rise of Nanotechnology in this field has reformed the existing drug delivery for targeting, diagnostic, remedial applications and patient monitoring. The convincing usage of nanotechnology in the conveyance of medications that prompts an extension of novel lipid-based nanocarriers and non-liposomal systems has been discussed. Present review deals with the late advances and updates in lipidic nanocarriers, their formulation strategies, challenging aspects, stability profile, clinical applications alongside commercially available products and products under clinical trials. This exploration may give a complete idea viewing the lipid based nanocarriers as a promising choice for the formulation of pharmaceutical products, the challenges looked by the translational process of lipid-based nanocarriers and the combating methodologies to guarantee the headway of these nanocarriers from bench to bedside.  相似文献   
6.
The objective of this study was to develop paclitaxel (PTX) loaded poly(ε-caprolactone) (PCL) based tiny implants. β-Cyclodextrin (β-CD) and polyethylene glycol (PEG 6000) were used to enhance solubility and release of the drug in the phosphate buffer saline pH 7.4. Implants were evaluated in terms of color, shape, thickness, surface area, weight, drug content. Developed implants were characterized for their surface morphology (SEM analysis), drug physical state by thermal analysis (DSC studies), crystalline nature (XRD studies) and drug excipients compatibility (FT-IR spectroscopy). Macroscopically all the tiny implants were white in color and cylindrical in shape with smooth surfaces. PTX was entrapped within implants in the polymeric amorphous form. In vitro drug release studies showed prolonged and controlled release of PTX with zero order and Korsmeyer–Peppas model being exhibited. Excipients and method of preparation did not affect chemical stability of PTX.  相似文献   
7.
Real-time screening of cellular response on the drugs could provide valuable insights for the early detection of therapeutic efficiency and the evaluation of disease progression. Cancer cells have the ability to vary widely in response to stress in a manner to adjust the signaling pathway to promote the survival or having a resistance to stimulation. Cell-based label-free technologies using electronic impedance sensor have strategies for constructing the signature profiles of each cells. To achieve exquisite sensitivity to substantially change of live-cell response have an important role that predict the potential of therapeutic effects. In this study, we use an impedance-based real-time cell analysis system to investigate dynamic phenotypes of cells described as a cellular index value. We show that gastric cancer cells generated characteristic kinetic patterns that corresponded to the treatment order of therapeutics. The kinetic feature of the cells offers insightful information that cannot be acquired from a conventional single end-point assay. Furthermore, we employ a ''sequential treatment strategy'' to increase cytotoxic effects with minimizing the use of chemotherapeutics. Specifically, treatment of paclitaxel (PTX) after down-regulating Akt gene expression using RNAi reduces the cell proliferation and increases apoptosis. We propose that the sequential treatment may exhibit more effective approach rather than traditional combination therapy. Moreover, the dynamic monitoring of cell-drug interaction enables us to obtain a better understanding of the temporal effects in vitro.  相似文献   
8.
目的 明确中国人每周紫杉醇和顺铂同步盆腔放疗早期宫颈癌术后患者的MTD。方法 顺序选择有高中危因素的早期宫颈癌术后患者25例,ECOG≤2。盆腔采用6、10 MV X线4个野3DCRT,照射剂量为40 Gy分20次后予盆腔中央挡铅,宫旁加量10~20 Gy分5~10次;192Ir高剂量率腔内照射,参考点为阴道黏膜下0.5 cm,处方剂量为5 Gy/次共2~4次。化疗起始剂量为每周紫杉醇 10 mg/m2、顺铂 20 mg/m2,共6个周期。利用3+3设计方法,每3例患者进行剂量递增直至达到DLT水平。结果 入组患者均在7周内完成外照射和腔内照射。第7剂量组4例患者中2例4周期后出现DLT即3级腹泻。3、4级血液学反应主要为白细胞、中性粒细胞减少,主要发生在4~6周期化疗后。第6剂量组1例出现4级白细胞、中性粒细胞减少,但额外增加的3例未出现4级反应。同步化疗未延迟治疗时间。25例患者中22例完成了6周期化疗。中位随访时间59.5个月,3例患者死于复发转移,1例死于呼吸衰竭。结论 早期宫颈癌术后盆腔照射联合每周紫杉醇和顺铂的同步放化疗安全、耐受性好。中国人的MTD为6周期的每周顺铂35 mg/m2和紫杉醇30 mg/m2。  相似文献   
9.
Pentraxin‐3 (PTX3), an acute‐phase protein released during inflammation, aids phagocytic clearance of pathogens and apoptotic cells, and plays diverse immunoregulatory roles in tissue injury. In neuroinflammatory diseases, like MS, resident microglia could become activated by endogenous agonists for Toll like receptors (TLRs). Previously we showed a strong TLR2‐mediated induction of PTX3 in cultured human microglia and macrophages by HspB5, which accumulates in glia during MS. Given the anti‐inflammatory effects of HspB5, we examined the contribution of PTX3 to these effects in MS and its animal model EAE. Our data indicate that TLR engagement effectively induces PTX3 expression in human microglia, and that such expression is readily detectable in MS lesions. Enhanced PTX3 expression is prominently expressed in microglia in preactive MS lesions, and in microglia/macrophages engaged in myelin phagocytosis in actively demyelinating lesions. Yet, we did not detect PTX3 in cerebrospinal fluid of MS patients. PTX3 expression is also elevated in spinal cords during chronic relapsing EAE in Biozzi ABH mice, but the EAE severity and time course in PTX3‐deficient mice did not differ from WT mice. Moreover, systemic PTX3 administration did not alter the disease onset or severity. Our findings reveal local functions of PTX3 during neuroinflammation in facilitating myelin phagocytosis, but do not point to a role for PTX3 in controlling the development of autoimmune neuroinflammation.  相似文献   
10.
目的检测非酒精性脂肪肝患者血清脂肪因子PTX3水平,并探讨PTX3与胰岛素抵抗以及氧化应激之间的相关性。方法用ELISA方法检测合并胰岛素抵抗的非酒精性脂肪肝患者41例(A组),单纯性非酒精性脂肪肝患者93例(B组)以及140例健康对照组(C组)血清PTX3脂肪因子水平,同时收集研究对象空腹胰岛素和糖脂代谢参数等资料。探讨PTX3与胰岛素抵抗之间的相关性。Logistic回归模型分析非酒精性脂肪肝合并胰岛素抵抗的危险因素;绘制ROC曲线,获得检测时脂肪因子PTX3对非酒精性脂肪肝合并胰岛素抵抗诊断效能。结果非酒精性脂肪肝组患者血清PTX3脂肪因子浓度均显著高于健康对照组[(3.2±1.2)ng/ml vs.(2.0±0.6)ng/ml,P=0.000];合并胰岛素抵抗的非酒精性脂肪肝组PTX3脂肪因子浓度均显著高于单纯性非酒精性脂肪肝[(4.5±1.2)ng/ml vs.(2.5±0.6 ng/ml),P=0.001]。相关分析表明PTX3脂肪因子与HOMA-IR(r=0.236,P=0.001),空腹血糖(r=0.312,P=0.012),MDA(r=0.004,P=0.001)呈正相关,但与GSH(r=-303,P=0.001)呈负相关。Logistic回归分析表明PTX3脂肪因子是非酒精性脂肪肝胰岛素抵抗的的独立因素(OR 1.45,95%CI:1.13~1.912,P=0.041),血清PTX3脂肪因子鉴别非酒精性脂肪肝是否合并胰岛素抵抗ROC曲线下面积为0.712,诊断非酒精性脂肪肝是否合并胰岛素抵抗最佳截点为3.86 ng/ml(敏感度:51.9%,特异度:94.5%,P=0.012),进一步以PTX3脂肪因子截点为参照,在非酒精性脂肪肝患者中当血清PTX3脂肪因子高于3.86 ng/ml时合并胰岛素抵抗的风险增加(OR=3.6,95%CI:3.19~13.36,P=0.000)。多重线性回归分析提示GSH、超敏C反应蛋白、胰岛素抵抗指数为影响PTX3脂肪因子水平的独立相关因素。结论血清PTX3脂肪因子与胰岛素抵抗以及氧化应激密切相关,有助于非酒精性脂肪肝病情发展的评估。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号